News

Stories

See all

2021 Updates: Lilly's Global COVID-19 Response

View Story

Living With Osteoarthritis: The Importance of Being Heard

View Story

Your COVID-19 Treatment Journey: Our Antibodies Might Help

View Story

Consent forms for Jonee Drake (Lilly employee) and son Carter are located in CAR.

'A Day On – Not a Day Off': Honoring Dr. Martin Luther King Jr.’s Legacy

View Story

2020 Updates: Lilly's Global COVID-19 Response

View Story

Time to Tear Down the Rebate Wall

View Story


Press Releases

See all

Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

January 27, 2021

Tags |  Product

INDIANAPOLIS and SAN FRANCISCO and LONDON , Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with




New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent

January 26, 2021

Tags |  Product

- BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance - Results from more than 1,000 high-risk patients were consistent with previous data - Findings from BLAZE-4 trial provide data on lower doses of bamlanivimab and etesevimab together - Media and




Lilly Completes Acquisition of Prevail Therapeutics

January 22, 2021

Tags |  Corporate

INDIANAPOLIS , Jan. 22, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly , extending Lilly 's




Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents

January 21, 2021

Tags |  Product

INDIANAPOLIS , Jan. 21, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial – conducted in